About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Natalizumab High Titer Immunogenicity and Safety

NCT00516893·13 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Biogen

With

Elan Pharmaceuticals

Age

18–55

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of a relapsing form of MS
Must fall within the therapeutic indications stated in the locally approved label for natalizumab

You may not be if

Prior treatment with natalizumab
Considered by investigator to be immunocompromised

The record

StatusCompleted

PhasePhase 2

Taking part113

StartedOct 2006

UpdatedMay 15, 2014

Conditions

Multiple Sclerosis

Where13

Research Site
Washington D.C., District of Columbia, United States
Research Site
Maitland, Florida, United States
Research Site
Miami, Florida, United States

Clareo Health | Natalizumab High Titer Immunogenicity and Safety